International Conference on Stem Cells and Cancer (ICSCC-2012)

3rd International Conference on Stem Cells and Cancer (ICSCC-2012): 
Proliferation, Differentiation and Apoptosis,
27-30 October 2012,
Pune, India

The ICSCC-2012 will cover basic and applied research on DNA replication, DNA damage and repair mechanisms, proliferation, differentiation & apoptosis of all types of stem cells as well as all types of cancer cells. There will be discussions on various aspects of cancer research, cancer therapeutics, cancer diagnostics, anti-cancer drugs, molecular markers for cancer and stem cells, hematopoietic stem cells, embryonic stem cells, induced pluripotent stem cells, mesenchymal stem cells, cardiac and neuronal stem cells, epigenetic
regulation of cancer and stem cells, cancer stem cells, stem cell therapy, clinical trials on using stem cells for treating human and animal diseases, commercialization of stem cell technologies, application of nanotechnology in stem cells and cancer research, nanomedicine for cancer and allied diseases, and other topics related to stem cells and cancer research & treatment.

Some of the Speakers:


Dr. Keith Humphries, Canada
Dr. Christian Buske, Germany
Dr. Aly Karsan, Canada
Dr. Stefan Bohlander, Germany
Dr. Dirk Eick, Germany
Dr. Philipp Kaldis, Singapore
Dr. Dr. Prasanna Kolatkar, Singapore
Dr. Laxman Gangwani, USA
Dr. Vijay Rawat, Germany
Dr. Dana Branzei, Italy
Dr. Miranda Buitenhuis, Netherlands
Dr. Girdhari Lal, India
Dr. Arun Kumar Trivedi, India

Awards:
1. ICSCC Young Investigator Award 2012
2. Best Oral Presentation Award
3. Best Poster Presentation Award
4. Travel awards

For more information: http://www.icscc.in/

Pharma IPR India 2012

Conference Day 31 January 2012
International Showcase 1-2 February 2012
Mumbai, India





Day-1 Agenda
  • Outlining the scope and current scenario of Patent law in USA and highlighting the critical areas to evaluate their adoption by the pharmaceutical companies in their business strategies
  • Analysing the Drug Price Competition and Patent Term Restoration Act - “Hatch- Waxman Act” to evaluate the relevant implications on the global pharmaceutical industry
  • Analysing the important factors in the Paragraph IV filing to assess the emerging trends of implementing it as a successful business strategy
  • Updating on the latest reforms in the US Patent system to formulate strategies for business growth and prepare for the increased competition
  • Highlighting the opportunities for Biosimilars and analysing the current patent trends to help avail strategic business benefits in the US markets
  • Analysing the European patent system to provide updated insights into the major developments in the pharmaceutical industry
  • Updating on the current scenario of Supplementary Protection Certificate (SPCs) in the European patent system to understand its implications on the pharmaceutical companies
  • Highlighting the opportunity available for biosimilars and analyzing the current trends within their patenting to help in availing strategic business benefits in the European markets
  • Evaluating the patentability standards in the pharmaceutical industry to mitigate the risks involved in product launches and analysing the freedom to Operate (FTO) by studying the various Infringement cases in European market
Speakers:-


Parbuddha Ganguli,
CEO
Vision IPR, India

Komal Shah Bukhanwala,
Director
InnovarIP

Swati Veera,
Senior In-House Patent Attorney & Head-Patents
Piramal Life Sciences

Gopakumar G. Nair,
Gopakumar Nair Associates

Subramaniam Natarajan,
Subramaniam, Nataraj & Associates

Aaron F. Barkoff,Ph.D.,
Partner
McAndrews, Held & Malloy,USA
Register by calling Pallavi on +91 (022) 4046 1466 or emailing conferences-india@ubm.com and and don't miss out an opportunity to overcome your legal challenges
www.pharmaipr-india.com

Clinical Trial, Research and Data Management

Six Months Training
The eligibility for the program is Graduation/Post Graduation in Life Science

Program Objectives
The program would endow an introduction to the area of clinical trials, with more detailed coverage of some of the key issues to be considered in their design, analysis, documentation and interpretation.

Further the course aims to develop:
  • A theoretical and practical understanding of the issues involved in the design, conduct, analysis and interpretation of randomized controlled trials of health interventions.
  • Skills to scrutinize information, to critically analyze and carry out research, and to communicate effectively.
  • Describe the uses and applications of the main types of intervention studies: clinical trials and community trials.
  • Describe the essential features and stages in the conduct of a clinical trial, and the role of randomization, use of placebo, blinding / masking and intention-to-treat analysis.
  • Discuss the ethical issues involved in the conduct of a clinical trial.

Program Methodology
The prospective participants may join the program by submitting Application form with the necessary fees and attachments. The methodology for the program delivery would be:
  • Delivery of the lectures by the technically expertise Faculty.
  • Guest Faculty from industry and academia would deliver the lectures.
  • Along with the theoretical knowledge student would also get a chance to have a practical oriented understanding of the subject e.g. role of computers in Clinical Trials
  • E-learning platform via Moodle would also be employed for the classes.
  • Students would also be taken for Industrial and Hospitals visits to have an overview of the entire Clinical trial process.

Learning Outcome
After completion of the course the participant would be able to:
  • Have better understanding of Good Clinical Practice (GCP) and Standard Operating Procedures for Clinical Research.
  • Participate in design, conduct and management of Global Clinical Trials, conducted at multicentric sites in India and Overseas.

For further details and enquiries
BIOINFORMATICS INSTITUTE OF INDIA
C-56A/28, Sector - 62,
Noida - 201301
(INDIA)
Tel : 0120-432080

International Conference on Environmental Science and Technology

25 to 29 June 2012
Houston, United States
The deadline for abstracts/proposals is 31 December 2011

The conference will provide a multidisciplinary platform for environmental scientists, engineers,management professionals and government regulators to discuss the latest developments in environmental research and applications.

For more information:-
Enquiries: env-conference@AASci.org
Web address: http://www.AASci.org/conference/env/2012/index.html

BioCentury and BIO Healthcare Conferences

October 21 at 11:30 am
New York

BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel(R) (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD), which is in Phase III clinical development according to a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA). BioSante's first FDA-approved product is Elestrin(TM) (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other BioSante products are Bio-T-Gel(TM), a testosterone gel for male hypogonadism, for which an NDA is pending, licensed to Teva Pharmaceuticals, and an oral contraceptive in Phase II clinical development. 

Additional information is available online at: www.biosantepharma.com 

A live audio webcast of remarks by Mr. Simes, at the BioCentury conference may be accessed at http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=BPAX&item_id=4209619

National Conference on Biopharmaceuticals & Healthcare

Sir M Visvesvaraya Institute of Technology
Bangalore(University)
Last date to register:- 31 October 2011
Start on :- 4 November 2011

Biopharmaceuticals are defined as pharmaceuticals manufactured by biotechnology methods, with the products having biological sources, usually involving live organisms or their active components. This includes all recombinant proteins, monoclonal antibodies, vaccines, blood/plasma-derived products, non -recombinant culture-derived proteins, and cultured cells and tissues. The pharmaceutical industry has transformed itself into the biopharmaceutical industry as a result of the \"convergence\" of biotechnology and pharmaceutical technologies. The pharmaceutical industry, through adoption of new technologies and close relationships with biotech companies, has undergone a fundamental change resulting in new, revolutionary technologies. Biopharmaceuticals are no longer a subset of pharmaceuticals, with biopharmaceuticals now taking in all pharmaceutical and biotechnology companies, with a health care orientation.


The health care industry is one of the world\'s largest and fastest-growing industries. Combining medical technology and the human touch, the healthcare industry diagnoses, treats, and administers care around the clock, responding to the immediate needs and requirements. The delivery of health care services is the most visible part of any health care system, both to users and the general public. Improving access, coverage and quality of health services depends on how the services are organized and managed, and on the incentives influencing providers and users. Healthcare is literally of vital importance, and requires understanding of ethical and social as well as financial issues; yet healthcare is in great need of sensible economic policies to achieve value for money.

This congregation attempts to gather the leaders and stakeholders of these progressive fields, including venture capitalists, scientists, academicians, researchers, students and most importantly, the general public. The platform aims to update, discuss, network and exchange stimulating ideas on the most recent achievements in the different topics of Biopharmaceuticals & Healthcare. Through this conference we hope to achieve closer links/collaboration between scientists and engineers. We also aim at educating the general public and taking the fruits of research from lab level and realizing their potential benefits to society.

For more information go to :- http://abhyuday.co.in/
or
Dr. H. G. Nagendra
Professor & Head
Organising Secretary- BPHC2011
Bangalore 562 157
Department of Biotechnology
Hunasamaranahalli, via Yelahanka
Mobile : +91 9916303565
Email : nagshaila@gmail.com

International conference on Nanomaterials & Nanotechnology

Venue:- Conference centre at University of Delhi, India
Date:- 18-21 December, 2011

Topics include theoretical and experimental works on

Nano-Optoelectronics
- Nano-phosphors and Nano-photonics
- Radiation effects on Nano-phosphors and Nano-materials

Nano-Biomaterials & Biomedical
- Nano-materials/composites based Biosensors
- Nano-medicine, Drug Delivery and MRI imaging

Nano-Advanced Materials
- Magnetic nanoparticles
- Nanowhiskers
- CNT, Graphene, Nano-fibers and Nano-sheets, Nano-gels

Nano-Fabrication
- Synthesis of Nanostructured Materials, Thin Films, Quantum Dots, CNT’s by various Methods
- Self-assembled Nano-structured Systems and material

Computational Simulation and Theory
- Nano-computing (simulation works on Nano-materials and Devices)
- Theoretical Modelling and other works on Quantum Dots and Nano-materials.... and more......

Details for Abstract Submission:-Submit abstracts for keynote and plenary addresses, invited talks, oral and poster presentations by October 15, 2011.

Registration Fees



Foreign Delegate
US$ 500
Foreign Delegate (accompanying person)
US$ 250
Foreign Delegate (Student)
US$ 400
Indian Delegate from Industry
INR 7500
Indian Delegate from Academia
INR 5000
Indian Delegate (Student)
INR 3000
Indian Delegate (accompanying person)
INR 2000

Payment of ICNANO Registration Fee after 01st December 2011 following addition fee will be charged:
Additional fee for all category of Foreign Delegates: US$ 50/ Each
Additional fee for all category of Indian Delegate: INR 1000/ EachAdditional fee 50 USD or 100 INR will be charged for spot registration.

How to pay
Send your payment (registration and accommodation) through bank transfer.

Bank Details:-
Account Name:- VBRI press
Bank Name:- Bank of Baroda
Bank Address:- Saidabad, Allahabad
Account Number:- 11800200000294
Swift code:- BARBINBBXXX
Bank code:- 012
Branch code:- SAIDAB
IFSC code:- BARBOSAIDAB

Regarding registration and accommodation please contact
Prof. P.D. Sahare
E-mail: convener@icbn2011.com
Tel.: (+ 91) 11-27667793
Fax: (+91) 11-27667061
Cell: (+91) 9811438818